Project Grant R50CA278773
Award Date
9/11/24
Completion Date
8/31/29
Dollars Obligated
$177K
Federal Agency
National Cancer Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a 5-year, $678,927 Project Grant to The Medical College of Wisconsin to conduct a randomized study on improving adherence to oral endocrine therapy in breast cancer patients. The intervention involves routine symptom monitoring using patient-reported outcomes and clinical pharmacy team follow-up to help patients manage symptoms and barriers to taking their daily medications. The study aims to assess the impact on...
This Project Grant award for $527,159 from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), supports research to understand the fundamental biological mechanisms underlying the initiation and development of breast cancer in individuals with BRCA1 mutations. The key focus is on examining how DNA damage and aberrant cell fate changes in BRCA1-deficient mammary epithelial cells, particularly luminal progenitor cells, may lead to a...
The University of Miami was awarded a $447,340 Project Grant by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to investigate epigenetic mechanisms and vulnerabilities in endocrine-resistant breast cancer. The 5-year grant, starting on March 1, 2025, aims to identify novel therapeutic targets and improve survival rates for patients with metastatic, endocrine-resistant estrogen receptor positive (ER+) breast cancer. The research will focus on the role of the...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $607,634 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Mayo Clinic Jacksonville, a nonprofit corporation registered as Scott Lynch MD. The grant, effective January 1, 2025 through December 31, 2029, supports research to develop a first-in-class non-muscle myosin II inhibitor, MT-125, and evaluate its synergistic effects when combined with signal transduction inhibitors and...
The National Cancer Institute (NCI) awarded a $299,995 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, FL. The grant will fund a project to develop and validate computed tomography (CT) image-based biomarkers that can predict survival outcomes for patients with high-grade serous ovarian carcinoma (HGSOC), the most common and deadly type of epithelial ovarian cancer. The...
This $895,779 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance the science of brain metastases from HER2-positive breast cancer. The key products and services to be delivered under this 7-year grant include: Understanding the fundamental biology and genetic risk factors of HER2-positive breast cancer metastases to the brain through patient tissue-based research. Developing real-time visualization techniques to track cancer cells and...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
This Project Grant award, with Federal Grant ID R01CA289387, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $657,121 award will fund research at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL to develop a dendritic cell therapy for treating leptomeningeal disease (LMD), a rare and deadly complication of advanced stage breast cancer. The research aims to use polarized conventional type 1 dendritic cells...
The federal Project Grant award R21CA296527, totaling $249,645.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The award will fund research at Boston Children's Hospital to develop an advanced genetic engineering approach to generate tumor-specific B cells that can be used to study their role in tumor progression and explore their potential for adoptive immunotherapy. The goal is to redirect the specificity of B cells towards the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $112,052 to The Trustees of the University of Pennsylvania to conduct research aimed at overcoming treatment resistance in gynecological cancers. The key products and services to be delivered include: Testing new therapies that exploit survival pathways critical for cancers with CCNE1 amplification, which are often platinum-resistant. This includes evaluating biomarkers beyond...